1 section, aortic-root surgery, or death; somatic growth; and
the incidence of adverse events.
2 omes measured were recurrence of atrial tachyarrhythmia and
the incidence of adverse events.
3 y and depression, and also no difference in mortality or in
the incidence of adverse events.
4 The incidence of adverse events (
80.4% vs. 79.5%) and serious
5 tudied the changing patterns of radiopharmaceutical use and
the incidence of adverse events (
AEs) to PET radiopharmaceuti
6 The incidence of adverse events after hospital discharge in p
7 The primary outcome was
the incidence of adverse events among vaccine and placebo rec
8 The incidence of adverse events and deaths was similar in the
9 Records were searched for
the incidence of adverse events and failed examinations.
10 The incidence of adverse events and serious adverse events wa
11 There was no evidence of differences in
the incidence of adverse events between groups (events of gra
12 There were no differences in
the incidence of adverse events between the 2 groups.
13 There was no significant difference in
the incidence of adverse events between vaccinees and placebo
14 udies, which reported an intervention aimed toward reducing
the incidence of adverse events in surgical patients.
15 The incidence of adverse events included 73 immediate postpro
16 The incidence of adverse events of any grade and grade 3-4 wa
17 No differences in
the incidence of adverse events or laboratory or vital sign a
18 666 patients who received at least one dose of study drug,
the incidence of adverse events or serious adverse events did
19 The incidence of adverse events over a 3-month follow-up peri
20 The incidence of adverse events reported during the study was
21 The primary outcome measure was
the incidence of adverse events requiring medical emergency t
22 No new safety signals were observed for obinutuzumab, and
the incidence of adverse events was balanced between arms, wi
23 The incidence of adverse events was consistent with previous
24 The incidence of adverse events was generally comparable betw
25 The incidence of adverse events was generally similar in the
26 The incidence of adverse events was not different between gro
27 The incidence of adverse events was significantly higher in t
28 The incidence of adverse events was significantly lower in th
29 The incidence of adverse events was similar across all treatm
30 The incidence of adverse events was similar across interventi
31 The incidence of adverse events was similar across treatment
32 The incidence of adverse events was similar across treatment
33 The incidence of adverse events was similar among all study g
34 The incidence of adverse events was similar among groups.
35 The incidence of adverse events was similar between groups.
36 The incidence of adverse events was similar between PA101 and
37 Except for diarrhea,
the incidence of adverse events was similar between placebo a
38 The incidence of adverse events was similar between those ran
39 The incidence of adverse events was similar in all three grou
40 The incidence of adverse events was similar in the rolapitant
41 The incidence of adverse events was similar in the two groups
42 The incidence of adverse events was similar in the two groups
43 The incidence of adverse events was similar in the two groups
44 The incidence of adverse events was similar in the two groups
45 The incidence of adverse events was similar to that in studie
46 The incidence of adverse events was similar with ivacaftor an
47 The incidence of adverse events was stratified by the presenc
48 ial in any other neurocognitive or pregnancy outcomes or in
the incidence of adverse events,
which was low in both groups
49 Primary safety and immunogenicity outcomes were
the incidence of adverse events within 14 days of vaccination
50 There was almost twice
the incidence of adverse events worse than baseline in the ke